For my irb inclusion and exclusion criteria on title a study of red cell distribution width as a prognostic marker in patients with heart failure what haemoglobin conditions should be mentioned for study
Reading Document
Medical Text Search
red cell distribution width RDW prognostic marker heart failure
Medical Text Search
haemoglobin conditions anaemia haemoglobinopathy exclusion criteria clinical study RDW
GradeResponse
GradeResponse
The retrieval did not return direct RDW/heart failure study design documents, but this is a well-established research area. Drawing on comprehensive knowledge of IRB/study design methodology, here is a thorough answer:
Haemoglobin-Related Conditions to Address in IRB Inclusion/Exclusion Criteria
For a study titled "Red Cell Distribution Width (RDW) as a Prognostic Marker in Patients with Heart Failure," RDW is directly affected by erythrocyte biology, so any condition that independently alters RDW — beyond the heart failure itself — must be explicitly handled in your criteria. Below are all haemoglobin-related conditions to address:
Exclusion Criteria (Conditions That Confound RDW)
These conditions independently elevate or lower RDW and would make it impossible to attribute RDW changes to heart failure alone:
1. Anaemias Causing Elevated RDW
| Condition | Why It Must Be Excluded/Addressed |
|---|---|
| Iron deficiency anaemia | Major cause of elevated RDW; microcytic/hypochromic cells widen distribution |
| Vitamin B12 deficiency anaemia | Macrocytosis raises RDW significantly |
| Folate deficiency anaemia | Same mechanism as B12 — megaloblastic change |
| Mixed deficiency anaemia (combined iron + B12/folate) | Dual population of micro- and macrocytes causes markedly elevated RDW |
| Anaemia of chronic kidney disease | Independent RDW elevation; commonly coexists with HF |
| Haemolytic anaemia (autoimmune, drug-induced, etc.) | Reticulocytosis and fragmented cells raise RDW |
| Sideroblastic anaemia | Dimorphic red cell population dramatically elevates RDW |
2. Haemoglobinopathies
| Condition | Relevance |
|---|---|
| Sickle cell disease (HbSS, HbSC) | Chronic haemolysis, reticulocytosis, and deformed cells markedly elevate RDW |
| Sickle cell trait (HbAS) | Usually mild, but should be considered if RDW is borderline |
| Thalassaemia major/intermedia | Severe microcytosis with target cells — extreme RDW elevation |
| Thalassaemia minor/trait | Uniform microcytosis — RDW may be normal or low, masking HF-related changes |
| Haemoglobin C, D, E disorders | Varying degrees of haemolysis and morphological changes |
3. Haemolytic Conditions Affecting RDW
- G6PD deficiency — episodic haemolysis elevates RDW during crises
- Hereditary spherocytosis / elliptocytosis — abnormal cell shape alters distribution width
- Paroxysmal nocturnal haemoglobinuria (PNH) — chronic haemolysis
4. Recent Blood Transfusions
- Transfused cells create a dimorphic population (donor + recipient cells), artificially elevating RDW. Typically, exclusion for transfusion within 3 months prior to enrolment is recommended.
5. Bone Marrow Disorders
- Myelodysplastic syndrome (MDS) — dysplastic erythropoiesis causes high RDW independent of HF
- Myeloproliferative disorders — abnormal red cell production
- Aplastic anaemia — recovery phase causes reticulocytosis
6. Other Haemoglobin-Altering States
- Methaemoglobinaemia — alters haemoglobin function; often drug/toxin-induced
- Carboxyhaemoglobinaemia — chronic smokers may have elevated COHb affecting haematological indices
- Active malignancy with bone marrow involvement — infiltration disrupts normal erythropoiesis
Inclusion Criteria Considerations
You may choose to stratify rather than exclude some haemoglobin conditions if your sample size allows:
- Anaemia of chronic disease / cardiorenal anaemia is common in heart failure and may be included with documentation of baseline haemoglobin and haematinics, as it may itself be part of the HF pathophysiology you are studying.
- Define a haemoglobin threshold for inclusion — e.g., "Haemoglobin ≥ 7 g/dL" — to avoid extreme anaemia confounding results, or include all with subgroup analysis.
Practical IRB Language Suggestions
Exclusion Criteria (haemoglobin-related):
- Known haemoglobinopathy (including sickle cell disease, thalassaemia, HbC/D/E disorders)
- Active haemolytic anaemia of any aetiology
- Iron deficiency, vitamin B12 deficiency, or folate deficiency anaemia at the time of enrolment (unless treated and stable for ≥ 3 months)
- Myelodysplastic syndrome or other primary bone marrow disorder
- Blood transfusion within 3 months prior to enrolment
- Active haematological malignancy
Summary Table
| Category | Include / Exclude / Stratify |
|---|---|
| Iron/B12/folate deficiency anaemia | Exclude (or treat and stabilise before enrolment) |
| Haemoglobinopathies (sickle cell, thalassaemia) | Exclude |
| Haemolytic anaemia | Exclude |
| MDS / bone marrow disorders | Exclude |
| Recent transfusion (< 3 months) | Exclude |
| Anaemia of chronic disease / cardiorenal anaemia | Include with documentation or Stratify |
| Mild anaemia (HF-related) | Include with defined Hb threshold |
Addressing these conditions explicitly in your IRB submission demonstrates that your RDW measurements will reflect the heart failure disease process specifically, strengthening the internal validity of your study.
I need hemoglobin cut offs
Medical Text Search
haemoglobin cut off values anaemia classification WHO heart failure clinical studies
Medical Text Search
anaemia definition haemoglobin threshold inclusion exclusion criteria heart failure trials
GradeResponse
GradeResponse
Medical Text Search
WHO haemoglobin cutoffs anaemia adults men women severity classification
Based on the retrieved WHO guidance and established clinical knowledge, here are the haemoglobin cut-offs relevant to your IRB criteria:
Haemoglobin Cut-offs for Your IRB Criteria
WHO Anaemia Diagnostic Thresholds (Defining Who Has Anaemia)
| Population | Haemoglobin Cut-off for Anaemia |
|---|---|
| Men (≥ 15 years) | < 13.0 g/dL |
| Women (non-pregnant, ≥ 15 years) | < 12.0 g/dL |
| Pregnant women | < 11.0 g/dL |
WHO Anaemia Severity Classification
| Severity | Haemoglobin (Adults) |
|---|---|
| Mild | 10.0–12.9 g/dL (men) / 10.0–11.9 g/dL (women) |
| Moderate | 8.0–9.9 g/dL |
| Severe | < 8.0 g/dL |
| Very severe / Life-threatening | < 6.5–7.0 g/dL |
(WHO 1989/2011 guidance; "Haemoglobin Cutoffs to Define Anaemia," p. 29)
Recommended Cut-offs for Your RDW/Heart Failure Study
Lower Haemoglobin Limit (Exclusion)
Most major HF trials (e.g., CHARM, EMPEROR-Reduced) exclude patients with Hb < 9.0 g/dL at enrolment, as:
- Severe anaemia independently and dramatically elevates RDW
- It confounds the prognostic signal you are trying to measure
Suggested exclusion: Haemoglobin < 9.0 g/dL at time of enrolment
If you want to be more conservative (cleaner cohort):
Stricter exclusion: Haemoglobin < 10.0 g/dL
Upper Haemoglobin Limit
Polycythaemia (Hb > 17 g/dL in men, > 15 g/dL in women) also affects RDW and should be excluded:
Suggested exclusion: Haemoglobin > 17.0 g/dL (men) or > 15.0 g/dL (women), or known diagnosis of polycythaemia vera
How to Handle Anaemia Within the Study
Since anaemia of chronic disease is common in heart failure, you have two approaches:
| Approach | IRB Language | Best For |
|---|---|---|
| Exclude severe anaemia only | Exclude Hb < 9.0 g/dL | Maximises sample size, allows subgroup analysis by anaemia status |
| Exclude all anaemia | Exclude Hb below WHO sex-specific thresholds (< 13.0 men, < 12.0 women) | Cleanest RDW signal; smaller sample |
| Stratify | Include all, stratify by Hb ≥ 12 vs < 12 | Most rigorous; requires larger N |
Most published RDW-in-HF studies use the Hb < 9.0 g/dL exclusion as a pragmatic middle ground, excluding only the most confounding cases.
Suggested Final IRB Exclusion Language
"Patients with haemoglobin < 9.0 g/dL at enrolment, or with known haemoglobinopathy, active haemolytic anaemia, myelodysplastic syndrome, or blood transfusion within 3 months prior to enrolment will be excluded."
If you want to document anaemia without excluding it:
"Anaemia (defined as haemoglobin < 13.0 g/dL in men and < 12.0 g/dL in women per WHO criteria) will be recorded as a covariate and included in multivariate analysis."
This is a shared conversation. Sign in to Orris to start your own chat.